SWOT Analysis for Kilitch Drugs(I) Ltd. - Weakness

Add SWOT widget to your site/app

Companies with current TTM PE Ratio less than 3 Year, 5 Year and 10 Year PE

Strong Momentum: Price above short, medium and long term moving averages

Consistent Highest Return Stocks over Five Years - Nifty500

Mid-range Performer (DVM)

Relative Outperformance versus Industry over 1 Month

Company with high TTM EPS Growth

Annual Profit Growth higher than Sector Profit Growth

PEG lower than Industry PEG

High Momentum Scores (Technical Scores greater than 50)

Relative Outperformance versus Industry over 1 Week

Relative Outperformance versus Industry over 1 Month

Overbought by Money Flow Index (MFI)

Effectively using its capital to generate profit - RoCE improving in last 2 years

Effectively using Shareholders fund - Return on equity (ROE) improving since last 2 year

Efficient in managing Assets to generate Profits - ROA improving since last 2 year

Growth in Quarterly Net Profit with increasing Profit Margin (YoY)

Company with Low Debt

Increasing Revenue every quarter for the past 2 quarters

Annual Net Profits improving for last 2 years

Book Value per share Improving for last 2 years

Company with Zero Promoter Pledge

Recent Results : Growth in Operating Profit with increase in operating margins (YoY)

RSI indicating price strength

Biggest Price Gainers from Open

Top Gainers

Stocks Outperforming their Industry Price Change in the Quarter

Companies with growing costs YoY for long term projects

Stocks with Expensive Valuations according to the Trendlyne Valuation Score

Poor cash generated from core business - Declining Cash Flow from Operations for last 2 years

Declining Net Cash Flow : Companies not able to generate net cash

Average Bullish Trend - Stocks with Medium Trendlyne Momentum Score versus Benchmarks

Decline in Net Profit with falling Profit Margin (QoQ)